Clinical Trials Directory

Trials / Completed

CompletedNCT01732068

Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol

Phase II Study for the Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
51 (actual)
Sponsor
Universitair Ziekenhuis Brussel · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The purpose of the present study is to examine the level of ovarian response and the pregnancy rates among poor ovarian responders treated with a novel treatment protocol with 150μg corifollitropin alfa followed by 300IU hMG in a short GnRH agonist protocol.

Detailed description

Corifollitropin alfa reaches maximum concentrations (Cmax), between 25 and 45 h after injection , a time interval which is significantly shorter as compared to treatment with rFSH. The investigators hypothesized that this rapid increase in the serum FSH concentration may result in a significantly higher exposure of the small antral follicles to constant high levels of FSH during the early follicular phase, securing not only the recruitment of the follicles, but also the continued growth. In the current study the investigators examine whether administration of corifollitropin followed by 300IU hMG in a short GnRH agonist protocol may result in acceptable pregnancy rates in poor ovarian responders fulfilling the "Bologna criteria"

Conditions

Interventions

TypeNameDescription
DRUGTriptorelinTriptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
DRUGCorifollitropin alfaCorifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
DRUGhpHMG300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering

Timeline

Start date
2012-07-01
Primary completion
2013-05-01
Completion
2013-05-01
First posted
2012-11-22
Last updated
2013-05-09

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT01732068. Inclusion in this directory is not an endorsement.